Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1324-1330

  Wang, Shuhang ^a   An, Tongtong ^a   Wang, Jie ^a   Zhao, Jun ^a   Wang, Zhijie ^a   Zhuo, Minglei ^a   Bai, Hua ^a   Yang, Lu ^a   Zhang, Yan ^a   Wang, Xin ^a   Duan, Jianchun ^a   Wang, Yuyan ^a   Guo, Qingzhi ^a   Wu, Meina ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER TISSUE; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR RESISTANCE; WILD TYPE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLASMA; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 76749151984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2672     Document Type: Article

References (24)

1. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2007;13:2890-6.
2. Soung YH, Lee JW, Kim SY, et al. Mutational analysis of EGFR and K-RAS genes In lung adenocarcinomas. Virchows Arch 2005;446: 483-8.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-57.
4. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361: 958-67.
5. Suzuki Y, Orita M, Shiraishi M, et al. Detection of Ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymeRase chain reaction products. Oncogene 1990;5: 1037-43.
6. Camps C, Sirera R, Bremnes R, et al. Is there a prognostic role of KRAS point mutations in the serum of patients with advanced nonsmall cell lung cancer? Lung Cancer 2005;50:339-46.
7. Neri M, Cesario A, Granone P, et al. Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate. Lung cancer 2006;53:393-5.
8. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell. Lung cancer by combined analysis of epidermal growth factor receptor mutation, k-ras mutation, and akt phosphorylation. Clin Cancer Res 2006;12:2538-44.
9. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinoma to gefitinib or erlotinib. PLoS Med 2005;2:e17.
10. Gumerlock PH, Holland WS, Chen H, et al. Mutational analysis of KRAS and EGFR implicates KRAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib. ASCO Annual Meeting. 2005, (abstract NO. 7008).
11. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-32.
13. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma dna samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2689-91.
14. Kimura T, Holland WS, Kawaguchi T, et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci 2004;1022:55-60.
15. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and KRAS mutations in tumor and paired serum of resected non-smallcell lung cancer patients. Cancer Lett 2003;193:207-16.
16. Trombino S, Neri M, Puntoni R, et al. Mutations in KRAS codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin Chem 2005;51:1313-4.
17. Gautschi OB, Huegli A, Ziegler M, et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. However, contrasting results were also reported. Cancer Lett 2007;254: 265-73.
18. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring Kras mutations with the use of plasma DNA. J Natl Cancer Inst 2000; 92:918-23.
19. Uemura T, Hibi K, Kaneko T, Takeda S, Inoue S, Okochi O. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 2004;39:56-60.
20. Pasi A, Jeffrey J, Engelman A, et al. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
21. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
22. San Tam IY, Chung1 LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12:1647-53.
23. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and incombination with erlotinib. J Clin Oncol 2005;23:5900-9.
24. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26: 4268-75.